hES cell research model supported

Therapies derived from human embryonic stem (hES) cells promise to be the most stable and cost-effective modality for future medicines and deserve support from public and private funders, according to a commentary in The Lancet.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom